Synthesis, crystal structure, and anticancer studies of organoruthenium(II) p-cymene N-phenyldithiocarbamate complex

Ajibade, PA, Fatokun, AA and Paca, AM (2023) Synthesis, crystal structure, and anticancer studies of organoruthenium(II) p-cymene N-phenyldithiocarbamate complex. Journal of Molecular Structure, 1292. ISSN 00222860

[thumbnail of Synthesis crystal structure and anticancer studies of organoruthenium p-cymene N-phenyldithiocarbamate complex.pdf]
Preview
Text
Synthesis crystal structure and anticancer studies of organoruthenium p-cymene N-phenyldithiocarbamate complex.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (2MB) | Preview

Abstract

Organoruthenium(II) p-cymene N-phenyldithiocarbamate complex, [Ru(phdtc)(η⁶-p-cym)]₂, was synthesized and characterized by elemental analysis, spectroscopic techniques, and single crystal X-ray crystallography. The single crystal X-ray structure of the complex shows that the compound crystallizes in a monoclinic crystal system with a P21/c space group to form a centrosymmetric binuclear complex. The structure consists of two divalent ruthenium(II) ions, two N-phenyldithiocarbamato anions and two p-cymene molecules. Each N-phenyldithiocarbamato anion acts as a chelating ligand to one ruthenium(II) and a bridging ligand to second ruthenium(II) ion in a classic “three-legged piano-stool” arrangement with a pseudo-tetrahedral geometry. The geometry around the ruthenium(II) ions is completed through η6 coordination to the p-cymene carbon atoms. Anticancer studies showed that the compound is potently cytotoxic (complete kill between 10 and 50 μM) when tested up to 100 μM for up to 48 h against two cell lines, HeLa and MRC5-SV2, models of cervical and lung cancer, respectively, and in some instances outperformed the standard platinum-based anticancer drug cisplatin for cytotoxic potency, highlighting the anti-cancer prospect of the complex.

Item Type: Article
Subjects: Q Science > QD Chemistry
R Medicine > RS Pharmacy and materia medica
Divisions: Pharmacy and Biomolecular Sciences
Publisher: Elsevier
Date of acceptance: 13 July 2023
Date of first compliant Open Access: 28 July 2023
Date Deposited: 28 Jul 2023 15:08
Last Modified: 28 Jul 2023 15:15
DOI or ID number: 10.1016/j.molstruc.2023.136102
URI: https://ljmu-9.eprints-hosting.org/id/eprint/20383
View Item View Item